Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.
Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
The technology consists of two patent families which collectively enable the development of cost effective, off-the-shelf vaccines based on a proprietary dendritic cell subset for the treatment of solid tumour cancers. The technology overcomes certain key roadblocks previously associated with dendritic cell vaccine technology.
Incorporated in March 2021
Origin: Oxford University, Sir William Dunn School of Pathology